Literature DB >> 16082639

Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis.

Walter P Maksymowych1, Robert D Inman, David Salonen, Suhkvinder S Dhillon, Ruben Krishnananthan, Millicent Stone, Barbara Conner-Spady, Janice Palsat, Robert G W Lambert.   

Abstract

OBJECTIVE: To develop a feasible magnetic resonance imaging (MRI)-based scoring system for spinal inflammation in patients with spondylarthropathy that requires minimal scan time, does not require contrast enhancement, evaluates the extent of lesions in 3 dimensional planes, and limits the number of vertebral levels that are scored because MRI demonstrates characteristic inflammatory lesions in the spine of patients with ankylosing spondylitis (AS) prior to the development of typical features on plain radiographic.
METHODS: Our scoring method was based entirely on the assessment of increased signal denoting bone marrow edema on T2-weighted STIR sequences. Blinded MRI films were assessed in random order at 2 sites by 3 blinded readers at each of the 2 sites (the Universities of Alberta and Toronto). Intra- and interreader reliability was assessed by intraclass correlation coefficient. The 24-week response of patients with AS randomized to infliximab:placebo (8:3) was assessed by effect size and standardized response mean.
RESULTS: An initial analysis of all discovertebral units (DVUs) in the spine of 11 patients demonstrated a mean of 3.2 (95% confidence interval 3.2, 5.2) affected units, while limiting the scoring to a maximum of 6 units captured most of the affected units. We scanned 11 patients with AS with clinically active disease and 20 additional patients randomized to a 24-week trial of either infliximab or placebo. Intraobserver reproducibility for the 6-DVU STIR score ranged from 0.93 to 0.98 (P < 0.0001). Interobserver reproducibility of scores by readers from both sites was 0.79 (P < 0.0001) for status score and 0.82 (P < 0.0001) for change score. Analysis of pretreatment and posttreatment scores for all 20 patients randomized to infliximab/placebo showed a large degree of responsiveness (standardized response mean = 0.87). Reproducibility and responsiveness were only slightly improved by using contrast enhancement with gadolinium diethylenetriaminepentaacetic acid.
CONCLUSION: The Spondyloarthritis Research Consortium of Canada MRI index is a feasible, reproducible, and responsive index for measuring spinal inflammation in AS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16082639     DOI: 10.1002/art.21337

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  68 in total

Review 1.  [Ankylosing spondylitis--current state of imaging including scoring methods].

Authors:  C E Althoff; K G Hermann; J Braun; J Sieper
Journal:  Z Rheumatol       Date:  2006-12       Impact factor: 1.372

2.  Vertebral body corner oedema vs gadolinium enhancement as biomarkers of active spinal inflammation in ankylosing spondylitis.

Authors:  Y-X J Wang; J F Griffith; M Deng; T K Li; L-S Tam; V W Y Lee; K K C Lee; E K Li
Journal:  Br J Radiol       Date:  2012-05-17       Impact factor: 3.039

3.  Toll-like receptor 2 and 4 induced interleukin-19 dampens immune reactions and associates inversely with spondyloarthritis disease activity.

Authors:  T W Kragstrup; T Andersen; C Holm; B Schiøttz-Christensen; A G Jurik; M Hvid; B Deleuran
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

4.  Correlation between clinical and MRI disease activity scores in axial spondyloarthritis.

Authors:  James W MacKay; Sharief Aboelmagd; J Karl Gaffney
Journal:  Clin Rheumatol       Date:  2015-04-19       Impact factor: 2.980

5.  Increased interleukin (IL)-20 and IL-24 target osteoblasts and synovial monocytes in spondyloarthritis.

Authors:  T W Kragstrup; M N Andersen; B Schiøttz-Christensen; A G Jurik; M Hvid; B Deleuran
Journal:  Clin Exp Immunol       Date:  2017-05-02       Impact factor: 4.330

Review 6.  Clinical assessment and outcome research in spondyloarthritis.

Authors:  Robert B M Landewé; Astrid van Tubergen
Journal:  Curr Rheumatol Rep       Date:  2009-10       Impact factor: 4.592

7.  Serum prolidase level in ankylosing spondylitis: low serum levels as a new potential gold standard biomarker for disease activity.

Authors:  Sevgi Baspinar; Mehmet Kırnap; Osman Baspınar; Oguzhan Sıtkı Dizdar; Derya Kocer
Journal:  Rheumatol Int       Date:  2016-07-21       Impact factor: 2.631

Review 8.  Tools for monitoring spondyloarthritis in clinical practice.

Authors:  Astrid M van Tubergen; Robert B M Landewé
Journal:  Nat Rev Rheumatol       Date:  2009-10-06       Impact factor: 20.543

9.  Imaging in ankylosing spondylitis.

Authors:  Mikkel Ostergaard; Robert G W Lambert
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-08       Impact factor: 5.346

Review 10.  Progress in spondylarthritis. Spondyloarthritis: lessons from imaging.

Authors:  Walter P Maksymowych
Journal:  Arthritis Res Ther       Date:  2009-05-18       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.